- Trial phase
- Preclinical (IND-enabling)
- Time to market
- Unknown, at least 3-5 years if clinical trials succeed. The drug is still preclinical with no IND filed.
- Why 2/10
- CTX213 is a preclinical program with no hard dated catalyst (IND filing, PDUFA, or pivotal readout) scheduled within the next ~12 months. It is one of many pipeline assets at CRISPR Therapeutics, which has an approved product (CASGEVY) and multiple Phase 1/2 programs. Per the rubric, a preclinical program with no scheduled binary catalyst and representing a small part of a larger pipeline scores 2.
CTX213 is too early-stage to drive near-term CRSP stock movement. Investors should focus on CRISPR Therapeutics' nearer-term catalysts: CASGEVY commercial ramp, Phase 1/2 data for CTX310 (hypertriglyceridemia) and zugo-cel (autoimmune), and any IND filing announcement for CTX213. The diabetes program is a long-duration call option, not a near-term trading catalyst.
Price Chart
Executive Summary
CTX213 is CRISPR Therapeutics' next-generation, gene-edited stem-cell therapy for Type 1 diabetes, currently in preclinical/IND-enabling development. It replaces the earlier encapsulated candidate CTX211 with a "deviceless" approach, unencapsulated hypoimmune islet cells designed to evade immune attack. While preclinical data is encouraging and the company plans to move toward clinical trials, there is no IND filed, no registered trial, and no hard catalyst on the horizon. CTX213 is a small piece of CRISPR Therapeutics' broader pipeline, which is anchored by the approved CASGEVY and several Phase 1/2 assets in cardiovascular, autoimmune, and oncology indications. For a non-medical investor, CTX213 is a long-duration, high-risk/high-reward pipeline program with no near-term binary event.
How It Works
CTX213 is a "deviceless" beta-cell replacement therapy for Type 1 diabetes. It uses CRISPR-Cas9 gene editing to turn stem cells into insulin-producing islet cells that are engineered to be "hypoimmune", invisible to the patient's immune system. Unlike the earlier version (CTX211), CTX213 is not placed inside a protective capsule; it is injected directly, relying on its gene edits to avoid immune rejection without lifelong immunosuppressive drugs.
Trial Status
CTX213 is in preclinical development with no IND filed and no clinical trial registered on ClinicalTrials.gov as of mid-2026. It has demonstrated "compelling preclinical efficacy data via direct administration" according to company filings. The predecessor candidate CTX211 (encapsulated version) had a Phase 1/2 trial that was terminated, and data from that program informed the shift to CTX213. The company is advancing CTX213 toward clinical testing and plans to initiate clinical trials.
The Two-Sided Case
Upcoming Catalysts
- IND filing (no specific date announced)
- Initiation of first clinical trial (company stated plans as of Feb 2026 but no timeline given)
- Potential preclinical data presentations at medical conferences
Source Filing
The SecBot filing or press-release report that triggered this drug report:
CRISPR Therapeutics AG PRESS-RELEASE CRSP ·Originating report